Jump to: navigation, search

CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass330.464

WikiDoc Resources for Furazabol


Most recent articles on Furazabol

Most cited articles on Furazabol

Review articles on Furazabol

Articles on Furazabol in N Eng J Med, Lancet, BMJ


Powerpoint slides on Furazabol

Images of Furazabol

Photos of Furazabol

Podcasts & MP3s on Furazabol

Videos on Furazabol

Evidence Based Medicine

Cochrane Collaboration on Furazabol

Bandolier on Furazabol

TRIP on Furazabol

Clinical Trials

Ongoing Trials on Furazabol at Clinical Trials.gov

Trial results on Furazabol

Clinical Trials on Furazabol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Furazabol

NICE Guidance on Furazabol


FDA on Furazabol

CDC on Furazabol


Books on Furazabol


Furazabol in the news

Be alerted to news on Furazabol

News trends on Furazabol


Blogs on Furazabol


Definitions of Furazabol

Patient Resources / Community

Patient resources on Furazabol

Discussion groups on Furazabol

Patient Handouts on Furazabol

Directions to Hospitals Treating Furazabol

Risk calculators and risk factors for Furazabol

Healthcare Provider Resources

Symptoms of Furazabol

Causes & Risk Factors for Furazabol

Diagnostic studies for Furazabol

Treatment of Furazabol

Continuing Medical Education (CME)

CME Programs on Furazabol


Furazabol en Espanol

Furazabol en Francais


Furazabol in the Marketplace

Patents on Furazabol

Experimental / Informatics

List of terms related to Furazabol

Furazabol (Miotolan) is a derivative of the anabolic steroid stanozolol. It differs from stanozolol by having a furazan ring system in place of the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally and causes heptatoxicity in some individuals. The more intriguing characteristic of this steroid is that (unlike other anabolic steroids) furazabol has the ability to lower cholesterol levels.[citation needed]

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of Furazabol are a myth. In the 1970s, research studies showed that Furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol. It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that Furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.

Diversion of this obscure pharmaceutical steroid to the black market rarely occurred while it was being manufactured by Daiichi Seiyaku Company in Japan. However, a number of underground labs (UGL) have produced limited quantities of Furazabol in recent years. Additionally, a non-methylated derivative of Furazabol called Furaguno is currently being sold over-the-counter on the sport nutrition market in the United States in 2006 and 2007.

de:Furazabol nl:Furazabol